Poly Medicure Limited (POLYMED) — Financial Results | 7 August 2026(3 announcements)

Poly Medicure reported Q1 FY27 consolidated revenue of ₹525.4 crores, up 30.3% YoY, driven by 16.2% domestic growth and 36.7% international growth. Gross profit rose 39.7% to ₹385.6 crores with margin expanding to 73.4%. Operating EBITDA increased 17.7% to [amount context mismatch] crores, though PAT declined 8.4% to ₹85.3 crores due to higher finance costs and tax. The company highlighted strong cash reserves of ₹854.7 crores and appointed new leadership in India and Brazil. Key growth drivers include portfolio diversification into cardiology and renal care, with new product launches and acquisitions supporting long-term expansion plans.

Poly Medicure Limited announced approval of Q1 FY2026 unaudited financial results showing consolidated revenue of ₹55,878.45 crores and paid-up capital increased to [amount not verified] after issuing 1,975 shares at ₹100 each under its ESOP scheme. The filing confirms no material misstatements in the limited review and includes regulatory compliance disclosures.

Poly Medicure Limited announced on 7 August 2026 its Q1 FY2026 results, showing a 69.9% YoY revenue jump to [amount not verified] and a 100% net profit surge to [amount not verified], driven by strong overseas performance across 13 subsidiaries. The Board approved ESOP grants and allotments, reappointed Jai Prakash & Company as cost auditors for 2026-27, and accepted Ravi Prakash’s resignation as Deputy Company Secretary effective 10 August 2026. Paid-up capital rose marginally to [amount not verified] after issuing 1.975 million shares at ₹100 premium per share under the 2020 ESOP scheme. The auditor’s limited review confirmed no material misstatements, though no formal audit opinion was issued.